All In Biotech

Free tool

FAERS Monitor: Bromsite

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 206911 or its brand name (Bromsite, Bromfenac Sodium). Reports on generic versions are filed under their own applications.

Reports

1,020

Serious

301

30% of reports

Hospitalization

101

Death reported

10

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • treatment failure146
  • product packaging quantity issue76
  • off label use75
  • product dose omission issue69
  • drug ineffective64
  • eye pain63
  • eye irritation58
  • product storage error39
  • product use issue36
  • visual impairment29
  • ocular hyperaemia28
  • product quality issue28
  • fatigue27
  • poor quality product administered27
  • vision blurred27

Reports by year received

View as table
YearReports
20061
20081
20091
20103
20112
201217
20137
20148
201517
201611
201788
2018105
201978
2020261
202173
202257
202375
202483
202563
202669

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,139 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
product packaging quantity issueSignal76139.6112.410,258
poor quality product administeredSignal2753.036.51,322
treatment failureSignal14636.431.35,002
eye painSignal6323.018.11,309
eye irritationSignal5820.816.21,075
ocular hyperaemiaSignal2812.28.4277
product storage errorSignal399.26.8278
product dose omission issueSignal694.83.9209
visual impairmentSignal294.83.485
product quality issueSignal284.33.067
vision blurredSignal274.12.860
product use issueSignal364.02.977
off label use751.81.425
drug ineffective641.00.80
fatigue270.70.53

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.